More than 3 million people in the United States suffer from peripheral neuropathy each year, a condition in which nerves outside of the brain and spinal cord are destroyed, resulting in pain and loss of feeling in the affected areas.
Peripheral neuropathy can be caused by diabetes, trauma, genetically inherited disease, infection, and other reasons.
Salk researchers identified a way to repair destroyed nerves in mice during peripheral neuropathy. They discovered that the protein Mitf aids in the activation of the repair function of the nervous system's specialist Schwann cells.
The findings, which will be published in Cell Reports, may inspire new therapeutics to increase repair function and heal peripheral neuropathy. "We wanted to know what mechanisms control damage response in peripheral nerves under varying conditions--like acute trauma, genetic disorders, or degenerative diseases," says senior author Professor Samuel Pfaff. "We found that Schwann cells, which are special cells in nerves that protect and support neurons' axons, enter their repair state because of a pathway mediated by the protein Mitf."
The peripheral nervous system is made up of all the nerves that branch out from the brain and spinal cord to give us sensation throughout our bodies.
There are many cell types in peripheral nerves, but Pfaff and his team focus on understanding neurons, which transmit information throughout the nervous system, and Schwann cells, which protect healthy neurons and repair damaged ones.
The peripheral nervous system's ability to repair damage is remarkable considering that the central nervous system--made up of the brain and spinal cord--is not able to repair damage. Yet, the mechanisms that orchestrate this feat have remained poorly understood.
To unravel how Schwann cells differentiate to begin repairing peripheral nerve damage, the researchers looked at mouse models of Charcot Marie Tooth disease (CMT), a type of hereditary neuropathy.
"Going into this project, I thought that when you have a genetic nerve degeneration disorder, cells are dying and recovery isn't possible," says first author Lydia Daboussi, a former postdoctoral researcher in Pfaff's lab and current assistant professor at UC Los Angeles. "But our findings show that there are gene programs turned on by Mitf that repair some of the damage done in those chronic disease scenarios, and when you turn those programs off, disease symptoms get worse."
In mice with CMT, the researchers noticed that the Schwann cells completing the repairs had high levels of Mitf in their nuclei--where the genetic instructions for how to be a Schwann cell and how to conduct repairs are stored.
Upon investigation of this relationship between Mitf and Schwann cells, they found that Mitf was in the cytoplasm of Schwann cells until sensing neuronal damage. Damage then prompted Mitf to relocate from the cytoplasm of the cell to the nucleus, where it would direct the Schwann cell to make repairs.
To validate the importance of Mitf in creating repair Schwann cells, the researchers removed Mitf altogether. In cases of both trauma and CMT, nerve repair was arrested in the absence of Mitf--demonstrating that Mitf is required for peripheral nerve repair and regeneration.
According to Daboussi, Mitf acts like a fire extinguisher. Always there, sitting in the Schwann cell, unnoticed until damage occurs. And when that damage occurs, Mitf is ready to go and immediately turns on the cell's repair functions.
Most surprising, noted Pfaff, was that Mitf was orchestrating these repairs during a chronic disease like CMT.
"Harnessing Schwann cell repair programs has great potential in treating chronic diseases," says Pfaff, also the Benjamin H. Lewis Chair at Salk. "It's possible that with targeted therapeutics, we can prompt more Schwann cells to repair peripheral nerve damage and push those repairs to completion in chronic cases. Furthermore, now that we have a better grasp on the repair mechanisms, we can see if it's possible to initiate repairs in the brain stem and spinal cord, too." (ANI)